Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Ford

Showing results (21-30 of 508) with videos related to

Pageof 51
Sort By:
International Journal of Hypertension|January 29, 2011
Improving blood pressure control in patients with diabetes mellitus and high cardiovascular riskHenry L Elliott, Suzanne M Lloyd, Ian Ford, et al.
European Heart Journal|November 1, 2012
The changing course of aortic valve disease in Scotland: temporal trends in hospitalizations and mortality and prognostic importance of aortic stenosisColin Berry, Suzanne M Lloyd, Yanzhong Wang, et al.
Plos One|September 24, 2013
Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention StudySarah J E Barry, Eleanor Dinnett, Sharon Kean, et al.
Lancet (London, England)|September 12, 2021
Cardiovascular safety of febuxostat - Authors' replyThomas M MacDonald, George Nuki, Michele Robertson, et al.
European Heart Journal|October 11, 2005
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable anginaJean-Claude Tardif, Ian Ford, Michal Tendera, et al.
Cardiovascular Drugs and Therapy|May 22, 2010
Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trialMichael G Hennerici, Michiel L Bots, Ian Ford, et al.
European Journal of Heart Failure|November 7, 2009
Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT)Karl Swedberg, Michel Komajda, Michael Böhm, et al.
Lancet (London, England)|September 2, 2008
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|May 2, 2023
Embedding a State-Wide Prescription Drug Monitoring Program into the Electronic Health RecordChad M Hodge, James Hellewell, Ian Ford, et al.
Age and Ageing|July 13, 2005
Predictors of functional decline in elderly people with vascular risk factors or diseaseAdriaan M Kamper, David J Stott, Michael Hyland, et al.
Pageof 51

Showing results (21-30 of 508) with videos related to

Sort By:
Pageof 51
International Journal of Hypertension|January 29, 2011
Improving blood pressure control in patients with diabetes mellitus and high cardiovascular riskHenry L Elliott, Suzanne M Lloyd, Ian Ford, et al.
European Heart Journal|November 1, 2012
The changing course of aortic valve disease in Scotland: temporal trends in hospitalizations and mortality and prognostic importance of aortic stenosisColin Berry, Suzanne M Lloyd, Yanzhong Wang, et al.
Plos One|September 24, 2013
Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention StudySarah J E Barry, Eleanor Dinnett, Sharon Kean, et al.
Lancet (London, England)|September 12, 2021
Cardiovascular safety of febuxostat - Authors' replyThomas M MacDonald, George Nuki, Michele Robertson, et al.
European Heart Journal|October 11, 2005
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable anginaJean-Claude Tardif, Ian Ford, Michal Tendera, et al.
Cardiovascular Drugs and Therapy|May 22, 2010
Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trialMichael G Hennerici, Michiel L Bots, Ian Ford, et al.
European Journal of Heart Failure|November 7, 2009
Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT)Karl Swedberg, Michel Komajda, Michael Böhm, et al.
Lancet (London, England)|September 2, 2008
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|May 2, 2023
Embedding a State-Wide Prescription Drug Monitoring Program into the Electronic Health RecordChad M Hodge, James Hellewell, Ian Ford, et al.
Age and Ageing|July 13, 2005
Predictors of functional decline in elderly people with vascular risk factors or diseaseAdriaan M Kamper, David J Stott, Michael Hyland, et al.
Pageof 51